Home > Newsletters > Devices & Diagnostics Letter > Misleading Imagery in Alzheimer’s PET Drug Lands Untitled Letter
Devices & Diagnostics Letter
Sept. 17, 2012 | Vol. 39 No. 37
Misleading Imagery in Alzheimer’s PET Drug Lands Untitled Letter
Eli Lilly has misbranded its radioactive PET drug Amyvid, approved for reviewing displays of brain scans using a black-and-white scale, by featuring a multi-colored brain image on a web page advertisement and other promotional materials for the product, according to an FDA untitled letter.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.